Format

Send to

Choose Destination
  • Showing results for a modified search because your search retrieved no results.
AIDS Res Hum Retroviruses. 2016 Dec;32(12):1187-1197. Epub 2016 Nov 21.

Humoral Antibody Responses to HIV Viral Proteins and to CD4 Among HIV Controllers, Rapid and Typical Progressors in an HIV-Positive Patient Cohort.

Author information

1
1 Department of Immunology and Microbial Science, The Scripps Research Institute , La Jolla, California.
2
2 Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences , Bethesda, Maryland.
3
3 Henry M. Jackson Foundation for the Advancement of Military Medicine , Bethesda, Maryland.
4
4 Laboratory of Viral Diseases, National Institutes of Allergy and Infectious Diseases, The National Institutes of Health , Bethesda, Maryland.
5
5 Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences , Bethesda, Maryland.

Abstract

The purpose of this study was to assess humoral antibody responses as a function of disease progression (DP) in a well-defined HIV+ cohort. We quantified antibodies to HIV-1 gp120, Gag, and CD4 receptor by enzyme-linked immunosorbent assay in sera from a cohort of 97 HIV+ subjects at defined stages of DP. We also measured antibody-dependent cellular cytotoxicity (ADCC) as a function of the clinical status of the patients. We purified antibodies to CD4 and gp120 and assessed them for specificity, ability to block gp120 binding to target cells, ability to block virus infection, and ability to facilitate ADCC. All of the HIV+ patient samples were positive for antibodies to HIV gp120 and p24 and 80% showed evidence of hypergammaglobulinemia. Approximately 10% of cohort members were positive for antibodies to CD4, but we noted no significant correlation relevant to DP. There were statistically significant differences between the groups concerning the level of humoral response to gp120 and Gag. However, we observed no distinction in ability of anti-gp120 antibodies purified from each group to neutralize infection. In addition, there was a statistically significant difference in ADCC, with elite controllers exhibiting significantly lower levels of ADCC than the other five groups. We detected IgA anti-gp120 antibodies, but did not correlate their presence with either DP or ADCC levels. The results are consistent with the interpretation that the humoral antibody response to the antigens assessed here represents a signature of the level of viremia but does not correlate with clinical status of HIV infection.

KEYWORDS:

ADCC; HIV; HIV clinical outcomes research; envelope

PMID:
27771962
PMCID:
PMC5175433
DOI:
10.1089/AID.2016.0182
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center